Edition:
United States

Redhill Biopharma Ltd (RDHL.OQ)

RDHL.OQ on NASDAQ Stock Exchange Capital Market

4.63USD
8 Dec 2017
Change (% chg)

$-0.32 (-6.46%)
Prev Close
$4.95
Open
$4.94
Day's High
$4.97
Day's Low
$4.62
Volume
69,276
Avg. Vol
41,511
52-wk High
$11.83
52-wk Low
$4.30

Chart for

About

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointes... (more)

Overall

No Ratios Available.

Financials

  Industry Sector
P/E (TTM): -- 186.11 15.67
EPS (TTM): -- -- --
ROI: -- -11.32 34.62
ROE: -- -35.69 16.00

BRIEF-Redhill Biopharma provides 2017 year-end business update

* REDHILL BIOPHARMA LTD - ‍COST REDUCTION PLAN IS IN PLACE TO GRADUALLY REDUCE AVERAGE QUARTERLY CASH BURN RATE IN 2018 TO APPROXIMATELY $8.5 MILLION​

Dec 05 2017

BRIEF-Redhill biopharma Q3 ‍loss per ordinary share US$0.09

* Redhill Biopharma reports 2017 third quarter financial results

Nov 13 2017

BRIEF-Redhill Biopharma says last patient enrolled in Phase III study with RHB-104 for Crohn’s disease

* Redhill Biopharma announces last patient enrolled in the Phase III study with RHB-104 for Crohn's disease

Nov 09 2017

BRIEF-RedHill Biopharma prices public offering of its American Depositary Shares

* RedHill Biopharma prices public offering of its American Depositary Shares

Nov 08 2017

BRIEF-Redhill Biopharma announces proposed public offering of its American Depositary Shares

* Redhill Biopharma announces proposed public offering of its american depositary shares Source text for Eikon: Further company coverage:

Nov 07 2017

BRIEF-IntelGenx and Redhill Biopharma resubmit Rizaport NDA to FDA

* Intelgenx and Redhill Biopharma resubmit Rizaport new drug application to the FDA

Nov 01 2017

BRIEF-Redhill Biopharma and Intelgenx submit new drug application to FDA for Rizaport® for migraines

* Redhill Biopharma and Intelgenx submit new drug application to FDA for Rizaport® for migraines

Nov 01 2017

BRIEF-RedHill Biopharma receives Notice of Allowance for a new U.S. patent covering RHB-104

* RedHill Biopharma receives Notice of Allowance for a new U.S. patent covering RHB-104

Oct 23 2017

BRIEF-RedHill Biopharma receives FDA Orphan Drug Designation for MESUPRON for pancreatic cancer

* RedHill Biopharma receives FDA Orphan Drug Designation for MESUPRON for pancreatic cancer

Oct 20 2017

RedHill Biopharma's bowel syndrome drug data fails to impress investors

RedHill Biopharma Ltd said on Tuesday its drug to treat diarrhea-predominant irritable bowel syndrome met the main goal in a mid-stage study, but the positive data failed to impress investors, sending its U.S.-listed shares lower.

Oct 03 2017

Earnings vs. Estimates